{"product_id":"alfasigma-pestle-analysis","title":"Alfasigma PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how regulatory shifts, healthcare spending trends, and innovation cycles are shaping Alfasigma’s strategic outlook—our concise PESTLE snapshot highlights the external forces that matter most to investors and strategists. Purchase the full PESTLE analysis for a detailed, actionable breakdown you can use in forecasts, investment cases, or strategic plans—download it now for instant access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean Healthcare Harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe European Commission’s push to centralize pharmaceutical rules, including the 2024 revision proposals for the Pharmaceutical Strategy, affects Alfasigma’s EU market access plans across 27 member states and could reduce approval timelines by an estimated 12–18%; alignment with the European Health Data Space rules (adopted in 2024 with phased implementation through 2026) requires upgraded patient-data governance and may increase compliance costs by ~€5–10m annually; mastering unified standards is key to preserving Alfasigma’s competitive position in a €380bn EU pharma market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs an Italian multinational, Alfasigma is exposed to EU–US–China trade dynamics; EU goods exports to the US were €491bn in 2024 and EU–China trade reached €880bn, meaning tariff shifts could materially affect revenue and input costs. Protectionist measures or API tariffs — which rose for some countries by up to 12% in 2023–24 — threaten supply-chain continuity and margins. The firm must track diplomatic indicators and reroute manufacturing or stockpile APIs to mitigate distribution and logistics risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Health Service Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Italian government’s 2025 budget increased Servizio Sanitario Nazionale funding to about €152bn, directly influencing reimbursement rates for Alfasigma’s core prescription portfolio and affecting margins on flagship gastroenterology products.\u003c\/p\u003e\n\u003cp\u003ePolitical prioritization of therapeutic areas—recently favoring oncology and vaccines—can divert resources away from gastroenterology, posing revenue headwinds or, if reversed, create windfalls for Alfasigma’s pipeline.\u003c\/p\u003e\n\u003cp\u003eFrequent changes in government since 2022 shifted healthcare spending priorities, requiring Alfasigma strategic agility to manage reimbursement risk and align product launches with evolving public procurement plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Security Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eParticipation in WHO-led programs and EU health security initiatives boosts Alfasigma's reputation and access to tenders; in 2024 public-sector contracts accounted for about 18% of its €1.1bn revenues, enhancing market reach.\u003c\/p\u003e\n\u003cp\u003ePolitical mandates for onshore production—seen in Italy's 2023 medicine sovereignty plan allocating €2.5bn—drive Alfasigma to prioritize local manufacturing investments.\u003c\/p\u003e\n\u003cp\u003eAlignment with global health security agendas improves crisis positioning: during COVID-19 Alfasigma supplied critical products, supporting resilience and continuity of supply.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% public-sector revenue exposure (2024)\u003c\/li\u003e\n\u003cli\u003e€1.1bn total revenue (2024)\u003c\/li\u003e\n\u003cli\u003eItaly's €2.5bn medicine sovereignty fund (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical pressure to lower medicine costs in the us and eu threatens margins proposals allow medicare negotiation target drugs with annual sales above million could affect alfasigma revenue mix where patented specialty products represent x of\u003e\n\u003cpnew frameworks in tying reimbursement to outcomes and enabling price negotiation for high-volume treatments may compress long-term forecasts requiring alfasigma adjust r roi models dcf assumptions.\u003e\n\u003cpalfasigma needs proactive government relations and real-world evidence to justify value-based pricing demonstrating quality-adjusted life-year gains cost-offsets can help defend during negotiations.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare negotiation scope: drugs \u0026gt;$100M annual sales\u003c\/li\u003e\n\u003cli\u003eEU outcome-based contracts rising in 2024–25\u003c\/li\u003e\n\u003cli\u003eValue evidence (QALYs, cost offsets) critical for pricing defense\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/palfasigma\u003e\u003c\/pnew\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU pharma centralization hikes €5–10m costs, pressures pricing; Italy fund fuels local manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEU regulatory centralization (Pharma Strategy 2024; EHDS phased to 2026) raises compliance costs ~€5–10m\/y and may cut approval times 12–18%; Italy’s €2.5bn medicine sovereignty fund and increased NHS budget (€152bn, 2025) favor local manufacturing; 18% public-revenue exposure of €1.1bn (2024) and US Medicare negotiation (drugs \u0026gt;$100m) pressure pricing, driving need for real‑world evidence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e€1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic revenue share (2024)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eItaly medicine fund (2023)\u003c\/td\u003e\n\u003ctd\u003e€2.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNHS budget (2025)\u003c\/td\u003e\n\u003ctd\u003e€152bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance cost impact\u003c\/td\u003e\n\u003ctd\u003e€5–10m\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Alfasigma across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section backed by current data and trend-based insights to identify risks and opportunities relevant to the pharmaceutical and healthcare markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Alfasigma’s PESTLE into a concise, shareable brief that highlights regulatory, market, and innovation risks for quick alignment in meetings or slide decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising costs for raw materials, energy and specialized labor have squeezed Alfasigma’s margins, with global pharmaceutical input prices up about 12% in 2024 and European industrial energy costs averaging 18% higher year‑on‑year; this challenges the company given regulated markets where drug prices often remain fixed. Strategic procurement, hedging and investments in energy‑efficient manufacturing—CapEx rose 9% in 2024—are essential to offset margin erosion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating across Europe, North America and LATAM exposes Alfasigma to EUR\/USD and local currency swings; in 2024 the euro weakened ~3.5% vs the dollar, impacting export competitiveness and compressing USD-denominated margins on reported revenue of €941m in 2023.\u003c\/p\u003e\n\u003cp\u003eCurrency moves can revalue international sales—about 38% of Alfasigma revenue from non-euro markets—creating translation risk that affected 2024 H1 reported growth trends.\u003c\/p\u003e\n\u003cp\u003eActive hedging (forwards, options) and localized cash-flow management are necessary to shield EBITDA, given historical FX volatility where 1% EUR depreciation can reduce reported euro revenues by ~0.4–0.6% for the group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlfasigma's cost of capital for R\u0026amp;D and acquisitions is sensitive to ECB policy; the ECB deposit rate at 4.00% (Feb 2026) raises borrowing costs versus 2021-22 lows, increasing debt service on potential deals and refinancing. Higher rates compress deal activity and may defer M\u0026amp;A or capex, while stable\/declining rates—if ECB eases toward ~3%—would support more aggressive portfolio expansion and innovation cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutraceutical Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsumer spending power and economic stability directly affect demand for Alfasigma’s non-prescription nutraceuticals; global nutraceutical market reached about USD 429 billion in 2023 and is projected CAGR ~8% through 2028, but sales are income-sensitive.\u003c\/p\u003e\n\u003cp\u003eUnlike essential medicines, nutraceutical purchases drop faster with reduced disposable income and lower consumer confidence; during 2020–2023 downturns premium supplement segments saw volume declines up to 12% in some EU markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size ~USD 429B (2023), CAGR ~8% to 2028\u003c\/li\u003e\n\u003cli\u003eNutraceuticals more income-elastic than Rx medicines\u003c\/li\u003e\n\u003cli\u003eDownturns caused up to 12% volume drops in premium segments (2020–23 EU)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Infrastructure Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic growth in emerging markets—GDP in Sub-Saharan Africa grew ~3.5% in 2024 and Southeast Asia ~4.7%—opens expansion opportunities for Alfasigma into regions upgrading healthcare systems.\u003c\/p\u003e\n\u003cp\u003eRising public\/private hospital investment (global hospital capex projected at $1.3 trillion by 2026) increases demand for gastroenterology and vascular products, benefiting Alfasigma’s specialty portfolio.\u003c\/p\u003e\n\u003cp\u003eTracking regional GDP and healthcare spend per capita (e.g., India health expenditure growth ~8% CAGR 2021–24) helps prioritize high-potential entry markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEmerging market GDP growth identifies expansion targets\u003c\/li\u003e\n\u003cli\u003eHospital capex growth fuels demand for specialty treatments\u003c\/li\u003e\n\u003cli\u003eRegional healthcare spend metrics guide market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargin squeeze from rising costs \u0026amp; FX risk amid 8% nutraceutical growth and 4% ECB rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising input and energy costs (raw materials +12% 2024; EU industrial energy +18% YoY) squeezed margins; CapEx +9% in 2024. FX risk significant: euro -3.5% vs USD 2024; 38% revenue from non-euro markets (€941m 2023). ECB rate 4.00% (Feb 2026) raises borrowing costs; nutraceutical market USD 429B (2023), CAGR ~8% to 2028; emerging market GDP: SE Asia ~4.7% 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2023)\u003c\/td\u003e\n\u003ctd\u003e€941m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-euro rev\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutraceutical mkt\u003c\/td\u003e\n\u003ctd\u003eUSD 429B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eECB rate\u003c\/td\u003e\n\u003ctd\u003e4.00% (Feb 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAlfasigma PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Alfasigma PESTLE analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752002072953,"sku":"alfasigma-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alfasigma-pestle-analysis.png?v=1772236948","url":"https:\/\/growthsharematrix.com\/products\/alfasigma-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}